This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pulmonary hypertension in sarcoidosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pulmonary hypertension is a well described complication associated with an increased risk of mortality (1).

  • the incidence in a large Japanese study has been estimated to be around 5% (1)
  • it is elevated in 6 to 23% of patients at rest and in 43% with exertion (2)

The mechanism for pulmonary hypertension can be due to

  • fibrosis - the most common mechanism which results in obliteration of the pulmonary vessels
  • external compression from the enlarged lymphnodes
  • granulomatous infiltration of the pulmonary arterioles

Sildenafil has been reported to significantly improve the haemodynamic parameters but the effectiveness of other pulmonary vasodilator therapy is currently unknown (1)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.